A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirusAndrew Young, Keith J. Chappell, Naphak Modhiran et al.|PLoS Pathogens|2025Cited by 8
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I TrialKeith J. Chappell, Daniel Watterson, Francesca L. Mordant et al.|The Journal of Infectious Diseases|2025Cited by 1